Miragen Therapeutics (MGEN) Now Covered by Deutsche Bank

Deutsche Bank began coverage on shares of Miragen Therapeutics (NASDAQ:MGEN) in a report issued on Thursday morning, MarketBeat reports. The firm issued a buy rating and a $15.00 price objective on the medical research company’s stock.

MGEN has been the topic of several other research reports. Oppenheimer assumed coverage on Miragen Therapeutics in a report on Friday, January 12th. They set an outperform rating and a $13.00 price target on the stock. B. Riley assumed coverage on Miragen Therapeutics in a report on Friday, January 5th. They set a buy rating and a $15.50 price target on the stock. Chardan Capital reiterated a buy rating on shares of Miragen Therapeutics in a report on Tuesday, January 16th. Cann assumed coverage on Miragen Therapeutics in a report on Friday, January 12th. They set an outperform rating and a $13.00 price target on the stock. Finally, Wedbush reiterated a buy rating and set a $19.00 price target on shares of Miragen Therapeutics in a report on Friday, December 1st. One analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the stock. The stock currently has an average rating of Buy and a consensus target price of $16.59.

How to Become a New Pot Stock Millionaire

Miragen Therapeutics stock opened at $7.11 on Thursday. Miragen Therapeutics has a fifty-two week low of $5.01 and a fifty-two week high of $15.91. The company has a current ratio of 13.33, a quick ratio of 13.33 and a debt-to-equity ratio of 0.26. The company has a market capitalization of $214.52, a price-to-earnings ratio of -4.74 and a beta of 1.64.

Miragen Therapeutics (NASDAQ:MGEN) last posted its quarterly earnings results on Wednesday, March 14th. The medical research company reported ($0.29) EPS for the quarter, topping the consensus estimate of ($0.33) by $0.04. Miragen Therapeutics had a negative return on equity of 63.57% and a negative net margin of 662.30%. The business had revenue of $1.19 million for the quarter, compared to analyst estimates of $1.22 million. research analysts expect that Miragen Therapeutics will post -1.19 earnings per share for the current year.

In related news, insider Adam Scott Levy acquired 9,090 shares of Miragen Therapeutics stock in a transaction that occurred on Tuesday, February 13th. The shares were purchased at an average cost of $5.50 per share, for a total transaction of $49,995.00. Following the acquisition, the insider now owns 10,540 shares in the company, valued at $57,970. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Bruce Booth acquired 545,454 shares of Miragen Therapeutics stock in a transaction that occurred on Tuesday, February 13th. The stock was bought at an average price of $5.50 per share, for a total transaction of $2,999,997.00. The disclosure for this purchase can be found here. 44.40% of the stock is currently owned by insiders.

A number of institutional investors and hedge funds have recently modified their holdings of the stock. BlackRock Inc. raised its holdings in Miragen Therapeutics by 4.7% in the 4th quarter. BlackRock Inc. now owns 574,917 shares of the medical research company’s stock valued at $5,997,000 after buying an additional 25,704 shares during the period. Renaissance Technologies LLC purchased a new stake in Miragen Therapeutics in the 4th quarter valued at about $855,000. Deutsche Bank AG raised its holdings in Miragen Therapeutics by 437.4% in the 4th quarter. Deutsche Bank AG now owns 60,917 shares of the medical research company’s stock valued at $634,000 after buying an additional 49,581 shares during the period. Virtu Financial LLC raised its holdings in Miragen Therapeutics by 372.8% in the 4th quarter. Virtu Financial LLC now owns 51,896 shares of the medical research company’s stock valued at $541,000 after buying an additional 40,920 shares during the period. Finally, Bank of New York Mellon Corp raised its holdings in Miragen Therapeutics by 67.1% in the 4th quarter. Bank of New York Mellon Corp now owns 45,775 shares of the medical research company’s stock valued at $478,000 after buying an additional 18,374 shares during the period. Hedge funds and other institutional investors own 19.83% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Miragen Therapeutics (MGEN) Now Covered by Deutsche Bank” was posted by Ticker Report and is the sole property of of Ticker Report. If you are accessing this report on another site, it was illegally stolen and reposted in violation of international trademark & copyright law. The legal version of this report can be read at https://www.tickerreport.com/banking-finance/3301291/miragen-therapeutics-mgen-now-covered-by-deutsche-bank.html.

Miragen Therapeutics Company Profile

Signal Genetics, Inc is a commercial stage, molecular genetic diagnostic company. The Company is focused on providing diagnostic services that help physicians to make decisions concerning the care of cancer patients. The Company’s diagnostic service is the Myeloma Prognostic Risk Signature (MyPRS) test.

Analyst Recommendations for Miragen Therapeutics (NASDAQ:MGEN)

Receive News & Ratings for Miragen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Miragen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

AutoZone  Coverage Initiated by Analysts at Wells Fargo
AutoZone Coverage Initiated by Analysts at Wells Fargo
Textainer Group  Now Covered by Analysts at Compass Point
Textainer Group Now Covered by Analysts at Compass Point
Owens-Illinois  Releases Q2 Earnings Guidance
Owens-Illinois Releases Q2 Earnings Guidance
Sanmina  Posts Quarterly  Earnings Results, Beats Estimates By $0.05 EPS
Sanmina Posts Quarterly Earnings Results, Beats Estimates By $0.05 EPS
ConforMIS  Earns News Impact Score of 0.18
ConforMIS Earns News Impact Score of 0.18
Marchex  Getting Somewhat Positive News Coverage, Report Shows
Marchex Getting Somewhat Positive News Coverage, Report Shows


© 2006-2018 Ticker Report. Google+.